Author + information
- Dimitrios Karlis,
- Evangelos Oikonomou,
- Theodoros Zografos,
- Gerasimos Siasos,
- Christine Chrysohoou,
- Stela Brili,
- George Lazaros,
- Sotirios Tsalamandris,
- Georgia Vogiatzi,
- Angelos Papanikolaou,
- Alexios Antonopoulos,
- Georgios Georgiopoulos and
- Dimitris Tousoulis
Introduction: Omega-3 polyunsaturated fatty acids (PUFAs) exert anti-inflammatory properties and have been tested in patients with systolic heart failure (HF). Soluble suppression of tumorigenicity2, is a member of the interleukin 1 (IL1) receptor family and is released from cardiomyocytes and fibroblasts after mechanical strain.
Hypothesis: To examine the short term impact of omega-3 PUFAs on novel indices of left ventricle function and on the cardiac stress and fibrinogenesis process.
Methods: The study was carried out on two separate arms (omega-3 PUFAs-2gr/day- orplacebofor 8 weeks), in a cross-over double blind design. The study population consisted of 25 stable systolic HF patients of ischemic etiology. All subjects were evaluated at baseline and after completion of each treatment arm. Left ventricular (LV) function was assessed using LV ejection fraction (LVEF), determined by the biplane modified Simpson method, and LV global longitudinal strain (GLS). LV end diastolic pressures was assessed by the ratio of transmitral E wave to the mean E wave velocity of the mitral and lateral walls (E/e’). Serum levels of sST2 were measured at each examined day as a biomarker of inflammation, myocardial stress and fibrosis.
Results: Twenty five subjects (age 65±5yr) were included in the study. In the PUFA group a significant improvement in sST2 levels were observed at the end of the treatment period compared to pre-treatment levels [219 (161-362)ng/ml vs. 212(158-315)ng/ml, p=0.006]. In the placebo group there was no improvement at the end of the treatment period compared to pre-treatment levels (p=0.22). Importantly, a significant improvement in LV function as assessed by LVEF and GLS was observed only after PUFA treatment (35.4± 7.6% vs. 33.4±6.8%; p=0.032, and −11.6±3.3% vs. −10.1±2.9%; p=0.022, respectively) as well as on LV diastolic and systolic volume (110±22ml vs. 105±24ml, p=0.01; 78±25ml vs. 71±23ml, p=0.001, respectively) and on E/e’ ratio with omega-3 PUFA (10.8±3.21 vs. 9.49±1.65, p=0.03).
Conclusions: In systolic HF patients, short term treatment with omega-3 PUFAs downregulates levels of sST2 with a parallel improvement in indices of systolic and diastolic function.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1121-248
- 2017 American College of Cardiology Foundation